4q3u
From Proteopedia
(Difference between revisions)
(5 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
+ | |||
==Crystal structure of Schistosoma mansoni arginase in complex with inhibitor nor-NOHA== | ==Crystal structure of Schistosoma mansoni arginase in complex with inhibitor nor-NOHA== | ||
- | <StructureSection load='4q3u' size='340' side='right' caption='[[4q3u]], [[Resolution|resolution]] 2.50Å' scene=''> | + | <StructureSection load='4q3u' size='340' side='right'caption='[[4q3u]], [[Resolution|resolution]] 2.50Å' scene=''> |
== Structural highlights == | == Structural highlights == | ||
- | <table><tr><td colspan='2'>[[4q3u]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Q3U OCA]. For a <b>guided tour on the structure components</b> use [ | + | <table><tr><td colspan='2'>[[4q3u]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Schistosoma_mansoni Schistosoma mansoni]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Q3U OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Q3U FirstGlance]. <br> |
- | </td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MN:MANGANESE+(II)+ION'>MN</scene>, <scene name='pdbligand=NNH:NOR-N-OMEGA-HYDROXY-L-ARGININE'>NNH</scene | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.5Å</td></tr> |
- | + | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=MN:MANGANESE+(II)+ION'>MN</scene>, <scene name='pdbligand=NNH:NOR-N-OMEGA-HYDROXY-L-ARGININE'>NNH</scene></td></tr> | |
- | <tr | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4q3u FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4q3u OCA], [https://pdbe.org/4q3u PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4q3u RCSB], [https://www.ebi.ac.uk/pdbsum/4q3u PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4q3u ProSAT]</span></td></tr> |
- | + | </table> | |
- | <table> | + | == Function == |
+ | [https://www.uniprot.org/uniprot/Q6WVP6_SCHMA Q6WVP6_SCHMA] | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | The X-ray crystal structure of arginase from Schistosoma mansoni (SmARG) and the structures of its complexes with several amino acid inhibitors have been determined at atomic resolution. SmARG is a binuclear manganese metalloenzyme that catalyzes the hydrolysis of l-arginine to form l-ornithine and urea, and this enzyme is upregulated in all forms of the parasite that interact with the human host. Current hypotheses suggest that parasitic arginases could play a role in host immune evasion by depleting pools of substrate l-arginine that would otherwise be utilized for NO biosynthesis and NO-dependent processes in the immune response. Although the amino acid sequence of SmARG is only 42% identical with that of human arginase I, residues important for substrate binding and catalysis are strictly conserved. In general, classical amino acid inhibitors such as 2(S)-amino-6-boronohexanoic acid (ABH) tend to bind more weakly to SmARG than to human arginase I despite identical inhibitor binding modes in each enzyme active site. The identification of a patch on the enzyme surface capable of accommodating the additional Calpha substitutent of an alpha,alpha-disubstituted amino acid inhibitor suggests that such inhibitors could exhibit higher affinity and biological activity. The structures of SmARG complexed with two different alpha,alpha-disubstituted derivatives of ABH are presented and provide a proof of concept for this approach in the enhancement of enzyme-inhibitor affinity. | ||
+ | |||
+ | Crystal Structure of Schistosoma mansoni Arginase, a Potential Drug Target for the Treatment of Schistosomiasis.,Hai Y, Edwards JE, Van Zandt MC, Hoffmann KF, Christianson DW Biochemistry. 2014 Jul 22;53(28):4671-84. doi: 10.1021/bi5004519. Epub 2014 Jul, 9. PMID:25007099<ref>PMID:25007099</ref> | ||
+ | |||
+ | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
+ | </div> | ||
+ | <div class="pdbe-citations 4q3u" style="background-color:#fffaf0;"></div> | ||
+ | |||
+ | ==See Also== | ||
+ | *[[Arginase 3D structures|Arginase 3D structures]] | ||
+ | == References == | ||
+ | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: | + | [[Category: Schistosoma mansoni]] |
- | [[Category: | + | [[Category: Christianson DW]] |
- | [[Category: | + | [[Category: Edwards JE]] |
- | [[Category: | + | [[Category: Hai Y]] |
- | [[Category: | + | [[Category: Hoffmann KF]] |
- | [[Category: | + | [[Category: Van Zandt MC]] |
- | + |
Current revision
Crystal structure of Schistosoma mansoni arginase in complex with inhibitor nor-NOHA
|